HomeAI · summaries
Storia in 3 fonti
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for its top-selling | With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain a label expansion for its top-selling product, dwarfism drug Voxzogo.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows
Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,
- ·
biopharmadive.com
BioMarin notches win in study that could expand use of top-selling medicine
The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.
- ·
Lilly, AbbVie, J&J, AZ lead an uptick in Big Pharma Q1 growth, with Novo again bringing up the rear
Biopharma sales trended upward in the first quarter of this year as eight of the industry’s top-25 companies achieved double-digit year-over-year growth, which was an uptick from…
- ·
With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California biotech appears set up to gain a label expansion for…
- ·
endpoints.news
BioMarin to seek further approval of Voxzogo in form of short stature
BioMarin Pharmaceutical will seek expanded approval for its bone growth-stimulating drug Voxzogo after the shot improved growth speed in children with a form of short stature, the…
- ·
Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. | Merck & Co. and Kelun-Biotech's sac-TMT is on fire…
- ·
AbbVie, GSK race up patient reputation leaderboard in the UK
AbbVie and GSK have surged up the rankings of the pharma companies with the best reputations among U.K. patient groups, contributing to turnover at the top of the leaderboards. |…
- ·
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
Less than a month after an FDA advisory committee voted 6-3 | Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s…